Alcon Inc. Q4 2025 Earnings Call Summary

Core Insights - Performance in 2025 showed resilience in softer markets, with a strong fourth-quarter exit driven by a productive launch cycle across Surgical and Vision Care [1] Surgical Portfolio - The Unity platform represents the largest upgrade opportunity in the surgical portfolio in over a decade, aimed at increasing throughput and case efficiency for surgeons [1] - PanOptix Pro has successfully stabilized trifocal share in the U.S. by addressing surgeon concerns regarding light scatter and visual disturbance profiles [1] Vision Care - Strategic focus in Vision Care is shifting toward the reusable segment, where the company is currently under-indexed but sees high patient loyalty and attractive margins [1] - The launch of Truqtra is tracking ahead of expectations, driven by high refill rates and a unique mechanism of action that stimulates natural tear production [1] Market Dynamics - Global cataract procedural volumes grew approximately 3% and contact lens markets grew around 4% in the fourth quarter [1] - Management attributes international IOL softness to competitive pressures and specific hospital-level reimbursement caps in China that limited AT-IOL adoption [1]